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Background-—Angiotensin-converting enzyme (ACE) plays a major role in blood pressure regulation and cardiovascular
homeostasis. Contrary to the assumption that ACE levels are stable, circulating ACE has been shown to be altered in obesity and
weight loss. We sought to examine effects of a high-saturated-fat (HF) diet on ACE within the NUtriGenomic Analysis in Twins
(NUGAT) study.
Methods and Results-—Forty-six healthy and nonobese twin pairs initially consumed a carbohydrate-rich, low-fat diet over a period
of 6 weeks to standardize for nutritional behavior prior to the study, followed by 6 weeks of HF diet under isocaloric conditions.
After 6 weeks of HF diet, circulating ACE concentrations increased by 15% (P=1.691030), accompanied by an increased ACE
gene expression in adipose tissue (P=3.89106). Stratiﬁcation by ACE rs4343, a proxy for the ACE insertion/deletion
polymorphism (I/D), revealed that homozygous carriers (GG) of the variant had higher baseline ACE concentrations (P=7.59108)
and additionally showed a 2-fold increase in ACE concentrations in response to the HF diet as compared to non- or heterozygous
carriers (AA/AG, P=29106). GG carriers also responded with higher systolic blood pressure as compared to AA/AG carriers
(P=0.008). The strong gene-diet interaction was conﬁrmed in a second independent, cross-sectional cohort, the Metabolic
Syndrome Berlin Potsdam (MeSyBePo) study.
Conclusions-—The HF-diet-induced increase of ACE serum concentrations reveals ACE to be a potential molecular link between
dietary fat intake and hypertension and cardiovascular disease (CVD). The GG genotype of the ACE rs4343 polymorphism
represents a robust nutrigenetic marker for an unfavorable response to high-saturated-fat diets.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01631123. ( J Am Heart Assoc. 2017;6:
e004465. DOI: 10.1161/JAHA.116.004465.)
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T he zinc metallopeptidase angiotensin-converting enzyme(ACE) plays an important role in blood pressure control
and cardiovascular homeostasis as a central regulatory
enzyme within the renin-angiotensin system (RAS). ACE
catalyzes the generation of the vasoconstrictor angiotensin
II from inactive angiotensin I and degrades the vasodilator
bradykinin. Its pharmacological inhibition represents a stan-
dard of care in the therapy of hypertension and related
cardiovascular disease (CVD). Carriers of a frequent inser-
tion/deletion (I/D) polymorphism located in the 16th intron of
the ACE gene (Alu I/D) are characterized by higher ACE levels
and have been shown, albeit inconsistently, to be associated
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with higher blood pressure and increased risk for CVD.1-3
Despite huge interindividual variability in circulating ACE
levels depending on the ACE genotype,4 circulating levels are
reported to be stable within given individuals.5 However, ACE
circulating concentrations or activity levels, which are highly
correlated,6,7 were shown to be increased in obesity8 and
decreased by weight loss.6,9,10 In addition to its predominant
expression in pulmonary endothelium as a primary source of
circulating levels, ACE is also expressed in adipose tissue11,12
with increased expression in response to overfeeding.13
We investigated the effects of an isocaloric diet high in
total and saturated fat on ACE within the framework of the
NUtriGenomic Analysis in Twins (NUGAT) study, which aimed
to identify nutrition-responsive genes and biomarkers and
their heritability. The cross-sectional Metabolic Syndrome
Berlin Potsdam (MeSyBePo) cohort, which includes nutritional




The study protocol was approved by the independent ethics
review committee of the Charite-Universit€atsmedizin Berlin in
accordance with the principles of the Helsinki Declaration of
1975, as revised in 2000. Written informed consent was
obtained from all participants prior to the study, which was
registered at ClinicalTrials.gov (Unique identiﬁer:
NCT01631123).
The study was conducted at the department of Clinical
Nutrition at the German Institute of Human Nutrition
Potsdam-Rehbr€ucke. Twin pairs were recruited either from a
twin register (HealthTwiSt, Berlin, Germany) or by public
advertisements. Exclusion criteria were consumptive dis-
eases, diabetes mellitus, high-grade anemia, renal failure,
moderate to severe heart diseases, angina pectoris, or stroke
in the last 6 months, food allergy, eating disorders, body
weight change ≥3 kg within 3 months prior to the study,
pregnancy or breastfeeding, drugs inﬂuencing metabolic
homeostasis, lipid and liver metabolism, or inﬂammation
(eg, systemic corticosteroids).
Participants were initially screened to determine their
eligibility for enrollment in the intervention study. This
screening visit comprised physical examination, medical
history, anthropometric measurements, and blood analysis.
Additionally, a standardized 3-hour, 75-g oral glucose toler-
ance test (OGTT) was performed. Participants’ resting energy
expenditure (REE) was measured by indirect calorimetry, and
physical activity level (PAL) was assessed by questionnaire to
calculate individual daily energy requirements. A total of 46
healthy and nonobese twin pairs, 34 monozygotic and 12
dizygotic, age 18 to 70 years and body mass index (BMI) 18
to 29 kg/m2 with BMI difference <3 kg/m2 between twins
were included in the study. The CONSORT Flow Diagram is
shown in Figure 1. Participants went from a 6-week, carbo-
hydrate-rich, low-fat diet (LF) to standardize for nutritional
behavior prior to the study to a 6-week HF diet in a sequential
design under isocaloric conditions (Figure 2). Three clinical
investigation days (CID) were performed, after 6 weeks of
low-fat diet (LF6) and after 1 and 6 weeks of high-saturated-
fat diet (HF1 and HF6). At each CID, anthropometric
measurements were performed. Three blood pressure read-
ings were taken in a relaxed sitting position with an
appropriate size cuff, and the average values were used for
analysis. Blood samples were drawn in the fasted state for
routine laboratory marker and biomarker analysis in plasma or
serum and SNP array-based genotyping. Additionally, a biopsy
of the subcutaneous adipose tissue was performed lateral to
the umbilicus by needle aspiration for microarray gene
expression analysis.
Dietary Intervention
All subjects completed a dietary record for 5 days prior to the
study to encompass dietary habits. They commenced with the
isocaloric dietary intervention for 6 weeks, receiving a high-
carbohydrate, low-fat diet (LF: 55% carbohydrate, 30% fat, 15%
protein) in accordance with accepted national dietary guide-
lines. After the ﬁrst investigation day (LF6) the diet was
changed to a low-carbohydrate, high-saturated-fat diet (HF:
40% carbohydrate, 45% fat, 15% protein) for 6 weeks with
emphasis on foods high in saturated fat such as red meat,
sausage, bacon, and full-fat dairy products. Participants
received a list of 94 food items and individual daily meal
plans on how to exchange and combine these foods, and
energy intake was adjusted according to body weight if
needed. To ensure compliance, participants were given
intensive, regular, and detailed dietary guidance by a nutri-
tionist over the entire period of intervention. For 1 week prior
to each particular CID, ~70% of the food was provided with
detailed daily meal plans to ensure a standardized dietary
pattern for all participants. All subjects had to complete 5
dietary records during the 12 weeks of the dietary interven-
tion period.
Blood Parameters
Determination of routine serum parameters (eg, total choles-
terol, HDL-cholesterol, triglycerides) was performed using an
automated analyzer (ABX Pentra 4000; ABX, Montpellier,
France). LDL cholesterol concentrations were calculated using
the Friedewald equation. ACE concentrations were measured
in the serum of all participants at each CID using a human
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ACE immunoassay ELISA kit (R&D Systems Inc, Minneapolis,
MN) with an interassay variance <5%.
Gene Expression Analysis
About 500 mg of subcutaneous adipose tissue were homog-
enized using a Speed Mill (Analytik Jena, Jena, Germany), and
total RNA was extracted by using the RNeasy Lipid Tissue Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Quality was assessed by using RNA 6000 Nano-
LabChips and Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). One microgram of each sample was
ampliﬁed using the Amino Allyl MessageAmpTM II aRNA
Ampliﬁcation Kit (Ambion by Life Technologies, Carlsbad,
CA) and hybridized onto Agilent Whole Human Genome
8960K Gene Expression Microarrays (Agilent Technologies,
Santa Clara, CA). Microarray data have been uploaded to NCBI
GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE62199; Accession No: GSE62199). To validate microarray
data, quantitative real-time PCR was performed. cDNA was
synthesized from 1 lg of RNA of each sample by using the
High-Capacity cDNA Reverse Transcription KitTM (Applied
Biosystems by Life Technologies, Carlsbad, CA). Samples
were labeled by Power SYBR Green Master Mix and detected
Figure 1. CONSORT ﬂow diagram of the NUGAT study. NUGAT indicates NUtriGenomic
Analysis in Twins; HF, high-saturated-fat diet; LF, low-fat diet.
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in triplicates in optical 384-well plates with the ABI ViiATM7
Real-Time PCR System (Applied Biosystems by Life Technolo-
gies, Carlsbad, CA). The samples were normalized to riboso-
mal protein L32 (RPL32), and the standard curve method was
used for evaluation. The primer sequences were ACE forward
primer CAAGCACCTGCACAGTCTCAAC, reverse primer TGAT
CGACGAGGTAGCTGAAGG; RPL32 forward primer CAACGT
CAAGGAGCTGGAAGT, reverse primer TTGTGAGCGATCTCGG
CAC.
Genotyping
Genomic DNA was isolated from buffy coat using a commer-
cial kit (NucleoSpin, Macherey-Nagel, D€uren, Germany) and
genotyped on HumanOmniExpressExome BeadChips (Illumina,
Inc, San Diego, CA) at the Interdisciplinary Center for Clinical
Research (IZKF, Leipzig, Germany).
Genotyping for the Metabolic Syndrome Berlin Potsdam
(MeSyBePo) study was performed using a predesigned rs4343
TaqMan SNP Genotyping Assay on 384-well plates using the
ABI ViiATM7 Real-Time PCR System (Applied Biosystems by Life
Technologies, Carlsbad, CA) according to the manufacturer’s
protocol.
Metabolic Syndrome Berlin Potsdam Study
The cross-sectional MeSyBePo study was approved by the
ethics commissions of Berlin and Brandenburg, Germany. All
individuals gave written informed consent prior to the study.
Two thousand three hundred sixty-four white volunteers were
randomly recruited from the Berlin and Potsdam areas. Four
hundred seventy-nine out of the 2364 participants were
excluded from the analyses due to missing data. Dietary data
were collected from 671 participants via a 4-day estimated
food record that comprised 18 categories with 151 food
items. By use of the German Nutrient Database BLS, version
2.3, the mean daily energy and nutrient intakes were
calculated. For evaluation of dietary fat intake, data on total
fat intake but not on saturated fat were available.
To analyze the inﬂuence of a high-fat dietary pattern on ACE
rs4343 genotype associations with blood pressure, we
excluded misreporting as a main source of error by evaluating
under-, normal, and overreporting of energy intake (EI).
Therefore, the basal metabolic rate (BMR) was calculated using
the Harris-Benedict equation. Based on the ratio of EI to BMR,
underreporting, normal, and overreporting of energy intake
were deﬁned as <1.35, 1.35 to 2.39 and ≥2.4, respectively.14
Statistical Analysis
For estimation of heritability, the “ACE” structural equa-
tion model was applied. This covariance analysis relies on
comparing the degree of concordance within and between
monozygotic versus dizygotic twin pairs and decomposes the
proportion of variance into (A) additive genetic inﬂuences and
(C) common environmental and (E) individual environmental
inﬂuences. The “ACE” model was calculated using R 2.15.0
plus OpenMX package. Genotype frequencies were analyzed
for deviation from the Hardy-Weinberg equilibrium by chi-
square test using R 3.1.2 plus Hardy-Weinberg package 1.5.5.
The evaluation of microarray data was performed using
Agilent GeneSpring GX Version 11 Software (Agilent Tech-
nologies, Waldbronn, Germany). The data set was normalized
to LF6, and genes with >1.5-fold changes were analyzed. The
statistical signiﬁcance of expression changes was calculated
by one way analysis of variance (ANOVA) and post hoc analysis
following a Mann-Whitney U test. P-values were adjusted for
multiple testing via the Benjamini-Hochberg (FDR) method.
The Kolmogorov-Smirnov test was used to assess variables
for normal distribution. Continuous variables with skewed
distribution were natural logarithm (ln)-transformed. One-way
or repeated-measures ANOVA followed by Bonferroni post
hoc test were used to compare mean values for continuous
data. To verify signiﬁcant results for nonnormally distributed
Figure 2. Time line of the NUGAT (NUtriGenomic Analysis in Twins) intervention study. For
1 week prior to each particular investigation day (hatched areas, weeks 6, 7, and 12) most of
the food was provided to ensure standardized dietary patterns for all participants. HF1
indicates investigation day after 1 week of the high-saturated-fat diet; HF6, investigation day
after 6 weeks of the high-saturated-fat diet; LF6, investigation day after 6 weeks of the
low-fat diet.
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data, the Kruskal-Wallis test was used. Additionally, linear
regression analyses were performed with adjustment for main
confounders. Correlation analyses were performed using
Pearson and Spearman rank correlation coefﬁcients for
variables with normal and skewed distributions, respectively.
Statistical signiﬁcance was deﬁned as P<0.05. Values are
expressed as meanSD unless otherwise stated. Statistical




Table 1 shows anthropometric and clinical characteristics of
the 92 healthy and nonobese participants at screening. As
calculated from dietary records, energy consumption from total
fat/saturated fat was 29%/10% for LF and 45%/18% for HF
diet, respectively. Energy consumption from carbohydrates and
protein was 55% and 16% for the LF diet and 41% and 15% for
the HF diet, respectively. Although the study was performed
under isocaloric conditions, the weight of participants
increased slightly (0.41.0 kg, P=99106). As expected,
LDL, HDL, and total cholesterol increased signiﬁcantly in




11 <0.001; Table 2), conﬁrming good compli-
ance of the participants with the dietary instructions.15
Effect of HF Diet on ACE Serum Concentrations
In response to the HF diet, fasting serum concentrations of
ACE increased by 15% (LF6 13941 ng/mL vs HF6
16149 ng/mL; repeated-measures ANOVA P=1.691030;
Figure 3). Changes in ACE were not inﬂuenced by changes
in body weight (linear regression, P=0.114). At each CID,
serum concentrations of ACE were signiﬁcantly correlated
with weight (LF6 q=0.461, HF1 q=0.474, HF6 q=0.423;
P<0.001), height (LF6 q=0.362, HF1 q=0.389, HF6
q=0.354; P<0.001), and thus also with BMI (LF6 r=0.315,
HF1 r=0.289, HF6 r=0.302; P<0.01), whereas no signiﬁcant
correlations were noted between ACE and systolic or
diastolic blood pressure despite a weak correlation between
ACE and systolic blood pressure at HF6 (r=0.234, P=0.025)
and between ACE and pulse pressure at HF6 (q=0.228,
P=0.029).
Both LDL and total cholesterol were not correlated with
ACE concentrations (LF6 P=0.765 and P=0.420). However,
the increase in ACE (ΔACE, HF6-LF6) was modestly but
signiﬁcantly correlated with the increase in LDL cholesterol
(q=0.296, P=0.004). Furthermore a modest negative correla-
tion was shown for ACE concentrations and HDL cholesterol
(LF6 q=0.278, HF1 q=0.277, HF6 q=0.350; P<0.01).
Effect of HF Diet on ACE mRNA Expression in
Subcutaneous Adipose Tissue
Adipose tissue ACE gene expression was signiﬁcantly
increased in response to the HF diet (HF6 vs LF6 1.412-
fold; ANOVA P=3.89106, post hoc HF6 vs LF6 P=0.023, and
HF6 vs HF1 P=0.007; Figure 4A).
To conﬁrm microarray data, we performed quantitative
real-time PCR where ACE mRNA expression was again
signiﬁcantly increased under HF diet conditions (repeated-
measures ANOVA, P=0.005; Figure 4B).
Table 1. Characteristics of the Participants Overall and Stratiﬁed for ACE rs4343 at Baseline in the NUtriGenomic Analysis in
Twins Study
Total AA Genotype AG Genotype GG Genotype P Value
n 92 31 44 17 0.842
Male/female 34/58 10/21 14/30 10/7 0.120
Age, y 3114 3014 3111 3420 0.764
BMI, kg/m2 22.82.7 22.82.2 22.92.7 22.93.6 0.990
SBP, mm Hg 11813 11612 11614 1258 0.044
DBP, mm Hg 749 737 749 8010 0.035
PP, mm Hg 439 438 429 4610 0.452
Total cholesterol, mmol/L 4.580.93 4.550.91 4.640.93 4.491.04 0.822
HDL cholesterol, mmol/L 1.380.35 1.380.30 1.450.39 1.200.27 0.043
LDL cholesterol, mmol/L 2.730.77 2.730.75 2.670.76 2.900.88 0.600
Triglycerides, mmol/L 0.990.44 0.970.47 1.010.43 0.970.39 0.935
Values are shown as meanSD. BMI indicates body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PP, pulse pressure; SBP, systolic
blood pressure.
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Heritability of Serum ACE
Figure 5 shows strong intrapair correlation of circulating ACE
concentrations in monozygous twins (LF6 r=0.867,
P=3.391011; Figure 5A), whereas intrapair ACE concentra-
tions were not correlated in dizygous twins (LF6 r=0.287,
P=0.366; Figure 5B). Based on the “ACE” structural equa-
tion model, estimated additive genetic effects contributed to
86%, and shared environmental inﬂuences to 14% of the
variance of circulating ACE concentrations, respectively. ACE
concentrations appeared to be one of the most highly heritable
markers in the NUGAT study, with similar heritability estimates
seen for bone mineral content (BMC) and height (Figure 5C).
Inﬂuence of the ACE rs4343 Polymorphism on
ACE Concentrations and Blood Pressure in
Response to the HF Diet
Because heritability is linked to genetics, we stratiﬁed our
analysis by genotypes of the ACE rs4343 variant; due to
strong linkage disequilibrium,16 this serves as a surrogate
marker for the ACE I/D polymorphism, where A2350
corresponds to the I-allele and 2350G corresponds to the
D-allele.17,18 Genotype frequencies for ACE rs4343 polymor-
phism were AA=31, AG=44, and GG=17 and did not deviate
from values predicted by the Hardy-Weinberg equilibrium
(v2=0.04, P=0.842). As shown in Figure 6A, ACE serum
concentrations signiﬁcantly differed depending on the geno-
type, with the lowest concentrations for homozygous noncar-
riers (AA), intermediate concentrations for heterozygous (AG),
and highest concentrations for homozygous carriers of the
variant (GG), respectively (ANOVA, LF6 P=4.791013, HF1
P=5.191013, and HF6 P=1.091014). The rs4343 genotype
accounted for 47% of the variance in ACE serum concentra-
tions (adjusted R2=0.466, P=4.291014). After sex
(P=4.59105) and BMI (P=0.031) had been included in the
model, rs4343 accounted for 60% of the variance (adjusted
R2=0.602, P=3.491018). An increase in ACE serum concen-
trations in response to the HF diet was conﬁrmed indepen-
dently of genotypes (repeated-measures ANOVA; AA
P=1.691011, AG P=2.691018, and GG P=3.19109),
although the increase was doubled for GG carriers compared
to AA or AG carriers (Figure 6B; P=29106, P-value adjusted
for sex, age, and BMI Padj=1910
5).
We further performed a bootstrap analysis to exclude bias
due to relatedness of twins, randomly assigning both subjects
of a twin pair to 1 of 2 data records, and both records were
analyzed separately. Random assignment of the twins was
repeated 10 000 times to prevent a bias, and group means,
standard deviations, and mean P-values were calculated. The
increase in circulating ACE levels differed signiﬁcantly
between rs4343 genotypes in both separately analyzed data
records (recessive model AA/AG vs GG: 181 ng/mL vs
384 ng/mL, P1=0.038 and P2=0.039).
Table 2. Characteristics of the Participants After the
Standardization (LF6) and After 1 and 6 Weeks of High-
Saturated-Fat Diet (HF1, HF6)
LF6 HF1 HF6 P Value
Weight, kg 66.611.7 66.511.6 67.011.8† <0.001
BMI, kg/m2 22.52.7 22.52.6 22.62.7† <0.001
SBP, mm Hg 11012 10912 11012 0.681
DBP, mm Hg 709 699 709 0.709












2.590.71 2.710.73* 2.860.79† <0.001
Triglycerides,
mmol/L
0.950.43 0.890.35 0.910.37 0.449
Values are shown as meanSD. BMI indicates body mass index; DBP, diastolic blood
pressure; HDL, high-density lipoprotein; HF1, investigation day after 1 week of the high-
saturated-fat diet; HF6, investigation day after 6 weeks of the high-saturated-fat diet;
LDL, low-density lipoprotein; LF6, investigation day after 6 weeks of the low-fat diet; PP,
pulse pressure; SBP, systolic blood pressure.
Repeated measures ANOVA with Bonferroni post hoc test: *P<0.05 compared to LF6,
†P<0.001 compared to LF6.
Figure 3. ACE serum concentrations at LF6, HF1, and HF6
(meanSD; ***P<0.001). ACE indicates angiotensin-converting
enzyme; LF6, investigation day after 6 weeks of the low-fat diet;
HF1, investigation day after 1 week of the high-saturated-fat diet;
HF6, investigation day after 6 weeks of the high-saturated-fat
diet.
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In Table 1, clinical characteristics at screening are sum-
marized, stratiﬁed by genotype. Compared to AA/AG carriers,
homozygous carriers of the polymorphism had lower HDL
cholesterol (recessive model, P=0.019, Padj=0.028) and
higher systolic and diastolic blood pressure (recessive model,
P=0.012 and P=0.011, Padj=0.087 and Padj=0.033, respec-
tively). This difference in systolic and diastolic blood pressure
did not persist at LF6 (AA/AG vs GG, 10913 mm Hg vs
1159 mm Hg, P=0.077, Padj=0.296; 699 mm Hg vs
727 mm Hg, P=0.154, Padj=0.346) and HF1 (AA/AG vs
GG, 10912 mm Hg vs 11311 mm Hg, P=0.120,
Padj=0.434; 699 mm Hg vs 718 mm Hg, P=0.304,
Padj=0.562). However, after the 6-week HF diet, systolic
blood pressure differed signiﬁcantly between genotypes (AA/
AG vs GG, 10812 mm Hg vs 1179 mm Hg, P=0.008,
Padj=0.033), whereas no differences in diastolic blood pres-
sure were detected (AA/AG vs GG, 699 mm Hg vs
737 mm Hg, P=0.105, Padj=0.158). Genotype-dependent
A
B
Figure 4. Results of ACE gene expression in subcutaneous
adipose tissue by (A) microarray analysis and (B) quantitative real-
time PCR. A, Values are presented as fold changes (HF1 vs LF6 and
HF6 vs LF6). P-values are shown after Benjamini-Hochberg
correction (*P<0.05, **P<0.01). B, Values are shown asmeanSD.
Bonferroni post hoc test was used to compare main effects (HF6 vs
LF6, P=0.010) of repeated-measures ANOVA (P=0.005). ACE
indicates angiotensin-converting enzyme; LF6, investigation day
after 6 weeks of the low-fat diet; HF1, investigation day after
1 week of the high-saturated-fat diet; HF6, investigation day after
6 weeks of the high-saturated-fat diet.
Figure 5. Intrapair correlation of ACE serum concentrations in
monozygotic (A) and dizygotic (B) twins (**P<0.01). Estimated
heritability (C) for ACE serum concentrations in comparison with
estimates for bone mineral content (BMC) and height: “A” additive
genetic effects, “C” common environmental inﬂuences, and “E”
unique environmental inﬂuences. ACE indicates angiotensin-
converting enzyme.
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differences in pulse pressure (PP) values failed to reach
statistical signiﬁcance after adjustment for sex, age, and BMI
(AA/AG vs GG, 398 mm Hg vs 447 mm Hg, P=0.026,
Padj=0.081).
By performing a bootstrap analysis to exclude bias due to
relatedness of twins, we could prove that systolic blood
pressure differed signiﬁcantly between genotypes in both data
sets (recessive model: 1081 mm Hg vs 1172 mm Hg,
P1=0.039 and P2=0.038). However, pulse pressure did not
differ signiﬁcantly between genotypes (recessive model:
391 mm Hg vs 442 mm Hg, P1=0.179 and P2=0.176).
Validation of ACE rs4343 Genotype Effects on
Blood Pressure in the MeSyBePo Study
A group of 1885 participants (1256 female and 629 male, age
5214, BMI 29.46.3 kg/m2) of the cross-sectional MeSy-
BePo cohort were included in the analysis to further validate
the interaction of dietary fat intake and ACE rs4343 genotype.
ACE rs4343 genotype frequencies were AA=346, AG=1023,
and GG=516, which differed signiﬁcantly from values pre-
dicted by the Hardy-Weinberg equilibrium (v2=16.77,
P=4.29105). Neither systolic nor diastolic blood pressure
(SBP, DBP) nor pulse pressure (PP) was signiﬁcantly associ-
ated with ACE genotype (additive model: PSBP=0.524,
PDBP=0.391, and PPP=0.309; recessive model PSBP=0.300,
PDBP=0.973, and PPP=0.144).
Possible misreporting of dietary intake was evaluated for a
total of 671 participants among whom 136 participants
(20.3%) underreported, 365 (54.4%) reported normally, and
170 (25.3%) overreported EI.
ACE rs4343 genotype frequencies for participants with
plausible reported energy intakes (n=365) were AA=66,
AG=197, and GG=102, which did not differ from values
predicted by the Hardy-Weinberg equilibrium (v2=2.96,
P=0.09). ACE rs4343 genotype was again not associated
with differences in SBP, DBP, or PP.
To examine the effects of dietary fat intake, we stratiﬁed
subjects into HF diet consumers with total energy from fat
greater than or equal to 37% (representing the average fat
intake in Western countries19) and normal or LF diet
consumers (<37% energy from fat). Mean total fat intake
accounted for 41% in the HF group and 31% in the normal/LF
group, respectively. Also, in this case, genotype frequencies
did not deviate from the Hardy-Weinberg equilibrium
(Table 3). For a reported dietary fat intake of <37%, no
genotype-speciﬁc differences were found, whereas for sub-
jects with dietary fat intake ≥37%, increased systolic blood
pressure and pulse pressure values were seen for GG carriers
compared to AA/AG carriers (additive model: PSBP=0.011 and
PPP=0.023, respectively, Table 3; recessive model:
PSBP=0.008, AA/AG vs GG 12216 mm Hg vs
13121 mm Hg, respectively; PPP=0.017 AA/AG vs GG
4612 mm Hg vs 5214 mm Hg, respectively). In a linear
regression model adjusted for sex, age, and BMI, the
association of the ACE rs4343 polymorphism with systolic
blood pressure and pulse pressure was highly signiﬁcant
(recessive model: bSBP=0.25 and PSBP=0.002; bPP=0.24 and
PPP=0.002). This model explained 27% of the variation in
systolic blood pressure (r2SBP=0.270) and 29% of the variation
in pulse pressure (r2PP=0.291). As expected, age (bSBP=0.418
and PSBP=3.45910
7; bPP=0.469 and PPP=1.09910
8) and
BMI (bSBP=0.208 and PSBP=0.010; bPP=0.179 and PPP=0.025)
had a signiﬁcant effect on systolic and pulse pressure,
whereas sex had no effect. The association of the ACE rs4343
polymorphism with systolic blood pressure and pulse pressure
remained signiﬁcant after further adjustment for total energy
intake, alcohol intake, smoking, and activity energy expendi-
ture (recessive model: bSBP=0.26 and PSBP=0.002; bPP=0.26
and PPP=0.003).
Figure 6. A, ACE serum concentrations at LF6, HF1, and HF6
stratiﬁed for ACE rs4343 genotype and (B) ΔACE (HF6–LF6)
stratiﬁed for ACE rs4343 genotype (meanSD; ***P<0.001). ACE
indicates angiotensin-converting enzyme; LF6, investigation day
after 6 weeks of the low-fat diet; HF1, investigation day after
1 week of the high-saturated-fat diet; HF6, investigation day after
6 weeks of the high-saturated-fat diet.
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The NUGAT study demonstrated that circulating ACE concen-
trations increase in response to a 6-week, high-saturated-fat
diet in healthy, nonobese subjects with a parallel increase in
adipose tissue ACE mRNA expression. To our knowledge, this
is the ﬁrst study reporting increased circulating ACE concen-
trations independent of body weight gain or obesity. Thus,
next to the well-known HF diet-induced increases in LDL-
cholesterol as an established CVD risk factor, we identiﬁed
ACE as a second parameter that is closely linked with
cardiovascular risk and that increases in response to HF diets.
Perhaps even more importantly, we identiﬁed the ACE
rs4343 polymorphism as a strong nutrigenetic marker that
powerfully modulates the extent of HF diet-induced increases
in ACE with parallel increases in blood pressure even in
healthy, nonhypertensive subjects. The frequent ACE rs4343
variant might therefore be linked to an increased risk of
cardiovascular disease, whereas ACE itself might constitute a
molecular link between total and saturated fat intake and
cardiovascular disease. Thus, our study shows that a nutri-
genetic approach offers real potential for providing person-
alized nutritional advice for disease prevention.
The strong gene-diet interaction we have identiﬁed may help
to explain inconsistent results in the relationship between ACE
levels or ACE genotype associations and blood pressure and
CVD.1-3,20-24 The assumption that ACE levels are associated
with blood pressure is due to the facts that ACE catalyzes the
production of angiotensin II and ACE inhibitors effectively
reduce blood pressure; however, this is not consistently
supported by all studies.7,25 A stratiﬁcation of total and
saturated fat intake by ACE genotype would be expected to
improve the risk estimates obtained in these studies. Remark-
ably, a recent epidemiological meta-analysis did not observe an
association between saturated/high fat intake and risk of
cardiovascular disease26 and therefore requested a change in
the dietary recommendations of the American Heart Associ-
ation. This data set should be particularly suitable for assessing
the interaction of ACE rs4343, diet, and cardiovascular risk.
With an estimated heritability of 86%, ACE appears to be 1
of the most heritable markers in our study, proving a high
genetic component in ACE concentrations. This heritability
estimate is considerably higher than the moderate values
being reported by both a family-based and twin-based
study27,28 but is most likely explained by the controlled diet
conditions underlying our study and might, therefore, be more
accurate. Moreover, our study possibly increased the concor-
dance among the monozygous twin pairs by excluding twins
with signiﬁcant differences in body weight.
A large proportion of the heritable variation of ACE
concentrations is strongly linked to the ACE gene, which
contains a series of frequent polymorphisms in strong
linkage disequilibrium with each other.17,29 The best known
is the ACE I/D polymorphism, which accounts for almost
50% of the interindividual variance in circulating ACE levels
and represents a quantitative trait locus (QTL).1,4,30,31
Numerous studies have explored associations of the ACE
I/D polymorphism, albeit inconsistently, with increased
blood pressure and increased risk for CVD.1-3,20-24 The
rs4343 SNP that was analyzed in our study is a silent
coding SNP expressed at the mRNA level and, due to
complete linkage disequilibrium, serves as a surrogate
marker for the I/D polymorphism.16-18 At baseline, homozy-
gous carriers of rs4343 (GG) had higher diastolic and by
trend higher systolic blood pressure compared to heterozy-
gous carriers and noncarriers (AA/AG). This difference did
not persist after 6 weeks of LF diet. This is most likely due
to the fact that blood pressure values improved in response
to the LF diet, which was in accordance to general national
dietary guidelines. After a challenge with the HF diet,
genotype-dependent differences in systolic blood reap-
peared again at HF6. These results were indicative of an
underlying gene-diet interaction. To validate these data, we
analyzed associations between rs4343 genotype and blood
pressure in a subcohort of the cross-sectional MeSyBePo
study for whom reliable nutritional data were available.
Indeed, whereas no associations between genotype and
blood pressure were detected for the whole cohort or for
subjects with normal fat intake, signiﬁcant genotype
differences were found in subjects with high dietary fat
intake, with the GG carriers having signiﬁcantly higher
Table 3. Dietary Fat Modiﬁed ACE rs4343 Genetic Effects on Blood Pressure in the Metabolic Syndrome Berlin-Potsdam Study
Fat Intake <37% Fat Intake ≥37%
AA AG GG P Value AA AG GG P Value
n 39 131 68 0.070 27 66 34 0.632
SBP, mm Hg 12717 12317 12419 0.385 12617 12015 13121 0.011
DBP, mm Hg 7711 7810 7810 0.885 7710 758 7910 0.132
PP, mm Hg 5011 4511 4613 0.061 4913 4511 5214 0.023
Values are shown as meanSD. ACE indicates angiotensin-converting enzyme; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
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systolic blood pressure and pulse pressure in comparison
to AA/AG carriers. Thus, we provided an independent
conﬁrmation of the gene-diet interaction.
The mechanism by which diets high in total and saturated
fat signal increases in ACE levels is unclear, but it was shown
that a diet with high lipid content activates the renin-
angiotensin system with increased ACE expression in adipose
tissue in mice.32 The high-lipid diet used was based on soy
bean oil, which is rich in unsaturated fatty acids, and therefore
stands in contrast to high-fat diets with characteristic high
content of saturated fat. However, palmitic acid, the major
saturated fatty acid, was shown to induce activation of the
renin-angiotensin system in 3T3-L1 adipocytes through toll-
like receptor 4 and NF-jB signaling.33
A limitation of our NUGAT intervention study is themoderate
number of participants with respect to genotype-related data
analysis. Nevertheless, we reduced confounding factors by
including only metabolically healthy, nonobese, and rather
young participants in the study, and ﬁnally, we demonstrated
that a healthy cohort might be favorable to study gene-diet
interactions that affect metabolic and/or cardiovascular risks.
Nevertheless, the results might be different in obese subjects,
and the results may not be applicable in other ethnicities
because ACE genotypes are more variable in nonwhites.34
Furthermore, nutritional intake information of our MeSy-
BePo study cohort is limited in that only data on total fat
intake but not on saturated fat were available. Nevertheless,
consuming high-fat diets typically stands for increased
saturated fat intake.
Our data suggest that a high total and saturated fat intake
alters concentrations of ACE in a nutrigenetic manner and
provides a potential pathway through which high intake of
total and saturated fats contributes to the pathogenesis of
cardiovascular diseases. Presumably, dietary strategies to
lower LDL cholesterol, which are reducing dietary total and
saturated fat (DASH diet, Dietary Approaches to Stop
Hypertension19), are equally efﬁcient in reducing ACE con-
centrations. Next to lowered LDL cholesterol concentrations,
reduced ACE concentrations might contribute concomitantly
to beneﬁcial effects.
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